APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense oligonucleotides (ASO) Drug and siRNA Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Analysis and Forecast 2026-2032

23 December 2025215 pages

Choose your research edition.

Industry ResearchAntisense oligonucleotides (ASO) Drug and siRNA Drug Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antisense oligonucleotides (ASO) Drug and siRNA Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antisense oligonucleotides (ASO) Drug and siRNA Drug include Novartis, Novo Nordisk, Biogen, AstraZeneca, WAVElife, Therapeutics, The WhiteOak Group, Inc., Sylentis and Sirnaomics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antisense oligonucleotides (ASO) Drug and siRNA Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Antisense oligonucleotides (ASO) Drug and siRNA Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antisense oligonucleotides (ASO) Drug and siRNA Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antisense oligonucleotides (ASO) Drug and siRNA Drug revenue, projected growth trends, production technology, application and end-user industry.

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Company

Novartis

Novo Nordisk

Biogen

AstraZeneca

WAVElife

Therapeutics

The WhiteOak Group, Inc.

Sylentis

Sirnaomics

Silence

Secarna

Sarepta Therapeutics

Quark Pharmaceuticals

ProQR

Miragen Therapeutics

Ionis

Genzyme

Exicure

Dicerna

Avidity Biosciences

Arrowhead

Alnylam

Akcea

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Type

Antisense Oligonucleotides (ASO) Drug

siRNA Drug

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Application

Chronic Liver Disease

Protein Deposition Disease

Single Gene Rare Disease

Others

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense oligonucleotides (ASO) Drug and siRNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense oligonucleotides (ASO) Drug and siRNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antisense oligonucleotides (ASO) Drug and siRNA Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antisense oligonucleotides (ASO) Drug and siRNA Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense oligonucleotides (ASO) Drug and siRNA Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antisense Oligonucleotides (ASO) Drug Major Player Table 3. siRNA Drug Major Player Table 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Chronic Liver Disease Major Player Table 6. Protein Deposition Disease Major Player Table 7. Single Gene Rare Disease Major Player Table 8. Others Major Player Table 9. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends Table 10. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Drivers Table 11. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Opportunities and Challenges Table 12. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Restraints Table 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2021-2026) Table 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2027-2032) Table 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Players (2021-2026) Table 20. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Players Headquarters & Area Served Table 22. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players, Product Type & Application Table 23. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2021-2026) Table 30. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2027-2032) Table 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2021-2026) Table 35. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2027-2032) Table 36. Novartis Company Information Table 37. Novartis Business Overview Table 38. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 40. Novartis Recent Development Table 41. Novo Nordisk Company Information Table 42. Novo Nordisk Business Overview Table 43. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 45. Novo Nordisk Recent Development Table 46. Biogen Company Information Table 47. Biogen Business Overview Table 48. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 50. Biogen Recent Development Table 51. AstraZeneca Company Information Table 52. AstraZeneca Business Overview Table 53. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 55. AstraZeneca Recent Development Table 56. WAVElife Company Information Table 57. WAVElife Business Overview Table 58. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 60. WAVElife Recent Development Table 61. Therapeutics Company Information Table 62. Therapeutics Business Overview Table 63. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 65. Therapeutics Recent Development Table 66. The WhiteOak Group, Inc. Company Information Table 67. The WhiteOak Group, Inc. Business Overview Table 68. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 70. The WhiteOak Group, Inc. Recent Development Table 71. Sylentis Company Information Table 72. Sylentis Business Overview Table 73. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 75. Sylentis Recent Development Table 76. Sirnaomics Company Information Table 77. Sirnaomics Business Overview Table 78. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 80. Sirnaomics Recent Development Table 81. Silence Company Information Table 82. Silence Business Overview Table 83. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 85. Silence Recent Development Table 86. Secarna Company Information Table 87. Secarna Business Overview Table 88. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 90. Secarna Recent Development Table 91. Sarepta Therapeutics Company Information Table 92. Sarepta Therapeutics Business Overview Table 93. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 95. Sarepta Therapeutics Recent Development Table 96. Quark Pharmaceuticals Company Information Table 97. Quark Pharmaceuticals Business Overview Table 98. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 100. Quark Pharmaceuticals Recent Development Table 101. ProQR Company Information Table 102. ProQR Business Overview Table 103. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 105. ProQR Recent Development Table 106. Miragen Therapeutics Company Information Table 107. Miragen Therapeutics Business Overview Table 108. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 110. Miragen Therapeutics Recent Development Table 111. Ionis Company Information Table 112. Ionis Business Overview Table 113. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 115. Ionis Recent Development Table 116. Genzyme Company Information Table 117. Genzyme Business Overview Table 118. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 120. Genzyme Recent Development Table 121. Exicure Company Information Table 122. Exicure Business Overview Table 123. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 125. Exicure Recent Development Table 126. Dicerna Company Information Table 127. Dicerna Business Overview Table 128. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 130. Dicerna Recent Development Table 131. Avidity Biosciences Company Information Table 132. Avidity Biosciences Business Overview Table 133. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 135. Avidity Biosciences Recent Development Table 136. Arrowhead Company Information Table 137. Arrowhead Business Overview Table 138. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 140. Arrowhead Recent Development Table 141. Alnylam Company Information Table 142. Alnylam Business Overview Table 143. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 145. Alnylam Recent Development Table 146. Akcea Company Information Table 147. Akcea Business Overview Table 148. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 150. Akcea Recent Development Table 151. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021-2026) & (US$ Million) Table 157. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (US$ Million) & (2027-2032) Table 158. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 159. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 160. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 161. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 162. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021-2026) & (US$ Million) Table 164. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (US$ Million) & (2027-2032) Table 165. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 166. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 167. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 168. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 170. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 171. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (US$ Million) & (2021-2026) Table 175. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Region (US$ Million) & (2027-2032) Table 176. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 177. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 178. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021-2026) & (US$ Million) Table 182. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (US$ Million) & (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Antisense oligonucleotides (ASO) Drug and siRNA Drug Image Figure 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antisense Oligonucleotides (ASO) Drug Image Figure 5. siRNA Drug Image Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Chronic Liver Disease Image Figure 9. Protein Deposition Disease Image Figure 10. Single Gene Rare Disease Image Figure 11. Others Image Figure 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032) Figure 25. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032) Figure 26. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Country (2021-2032) Figure 27. United States Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032) Figure 32. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032) Figure 33. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Country (2021-2032) Figure 34. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032) Figure 44. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032) Figure 45. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032) Figure 47. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032) Figure 48. Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Region (2021-2032) Figure 49. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotides (ASO) Drug
  • siRNA Drug
Applications
  • Chronic Liver Disease
  • Protein Deposition Disease
  • Single Gene Rare Disease
  • Others
Companies covered
  • Novartis
  • Novo Nordisk
  • Biogen
  • AstraZeneca
  • WAVElife
  • Therapeutics
  • The WhiteOak Group, Inc.
  • Sylentis
  • Sirnaomics
  • Silence
  • Secarna
  • Sarepta Therapeutics
  • Quark Pharmaceuticals
  • ProQR
  • Miragen Therapeutics
  • Ionis
  • Genzyme
  • Exicure
  • Dicerna
  • Avidity Biosciences
  • Arrowhead
  • Alnylam
  • Akcea

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Type
  3. 1.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antisense Oligonucleotides (ASO) Drug
  5. 1.2.3 siRNA Drug
  6. 1.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Application
  7. 1.3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Chronic Liver Disease
  9. 1.3.3 Protein Deposition Disease
  10. 1.3.4 Single Gene Rare Disease
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Dynamics
  1. 2.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends
  2. 2.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Drivers
  3. 2.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Opportunities and Challenges
  4. 2.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Perspective (2021-2032)
  2. 3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Growth Trends by Region
  3. 3.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Players
  2. 4.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Players Headquarters & Area Served
  7. 4.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players, Product Type & Application
  8. 4.5 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market CR5 and HHI
  11. 4.6.3 2025 Antisense oligonucleotides (ASO) Drug and siRNA Drug Tier 1, Tier 2, and Tier 3
5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type
  1. 5.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2032)
  3. 5.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2021-2032)
6 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
  1. 6.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2032)
  3. 6.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Novo Nordisk
  8. 7.2.1 Novo Nordisk Company Information
  9. 7.2.2 Novo Nordisk Business Overview
  10. 7.2.3 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  12. 7.2.5 Novo Nordisk Recent Developments
  13. 7.3 Biogen
  14. 7.3.1 Biogen Company Information
  15. 7.3.2 Biogen Business Overview
  16. 7.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  18. 7.3.5 Biogen Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 WAVElife
  26. 7.5.1 WAVElife Company Information
  27. 7.5.2 WAVElife Business Overview
  28. 7.5.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  30. 7.5.5 WAVElife Recent Developments
  31. 7.6 Therapeutics
  32. 7.6.1 Therapeutics Company Information
  33. 7.6.2 Therapeutics Business Overview
  34. 7.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  36. 7.6.5 Therapeutics Recent Developments
  37. 7.7 The WhiteOak Group, Inc.
  38. 7.7.1 The WhiteOak Group, Inc. Company Information
  39. 7.7.2 The WhiteOak Group, Inc. Business Overview
  40. 7.7.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  42. 7.7.5 The WhiteOak Group, Inc. Recent Developments
  43. 7.8 Sylentis
  44. 7.8.1 Sylentis Company Information
  45. 7.8.2 Sylentis Business Overview
  46. 7.8.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  48. 7.8.5 Sylentis Recent Developments
  49. 7.9 Sirnaomics
  50. 7.9.1 Sirnaomics Company Information
  51. 7.9.2 Sirnaomics Business Overview
  52. 7.9.3 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  54. 7.9.5 Sirnaomics Recent Developments
  55. 7.10 Silence
  56. 7.10.1 Silence Company Information
  57. 7.10.2 Silence Business Overview
  58. 7.10.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  60. 7.10.5 Silence Recent Developments
  61. 7.11 Secarna
  62. 7.11.1 Secarna Company Information
  63. 7.11.2 Secarna Business Overview
  64. 7.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  66. 7.11.5 Secarna Recent Developments
  67. 7.12 Sarepta Therapeutics
  68. 7.12.1 Sarepta Therapeutics Company Information
  69. 7.12.2 Sarepta Therapeutics Business Overview
  70. 7.12.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  72. 7.12.5 Sarepta Therapeutics Recent Developments
  73. 7.13 Quark Pharmaceuticals
  74. 7.13.1 Quark Pharmaceuticals Company Information
  75. 7.13.2 Quark Pharmaceuticals Business Overview
  76. 7.13.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  78. 7.13.5 Quark Pharmaceuticals Recent Developments
  79. 7.14 ProQR
  80. 7.14.1 ProQR Company Information
  81. 7.14.2 ProQR Business Overview
  82. 7.14.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  84. 7.14.5 ProQR Recent Developments
  85. 7.15 Miragen Therapeutics
  86. 7.15.1 Miragen Therapeutics Company Information
  87. 7.15.2 Miragen Therapeutics Business Overview
  88. 7.15.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  90. 7.15.5 Miragen Therapeutics Recent Developments
  91. 7.16 Ionis
  92. 7.16.1 Ionis Company Information
  93. 7.16.2 Ionis Business Overview
  94. 7.16.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  96. 7.16.5 Ionis Recent Developments
  97. 7.17 Genzyme
  98. 7.17.1 Genzyme Company Information
  99. 7.17.2 Genzyme Business Overview
  100. 7.17.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  102. 7.17.5 Genzyme Recent Developments
  103. 7.18 Exicure
  104. 7.18.1 Exicure Company Information
  105. 7.18.2 Exicure Business Overview
  106. 7.18.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  108. 7.18.5 Exicure Recent Developments
  109. 7.19 Dicerna
  110. 7.19.1 Dicerna Company Information
  111. 7.19.2 Dicerna Business Overview
  112. 7.19.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  114. 7.19.5 Dicerna Recent Developments
  115. 7.20 Avidity Biosciences
  116. 7.20.1 Avidity Biosciences Company Information
  117. 7.20.2 Avidity Biosciences Business Overview
  118. 7.20.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  120. 7.20.5 Avidity Biosciences Recent Developments
  121. 7.21 Arrowhead
  122. 7.21.1 Arrowhead Company Information
  123. 7.21.2 Arrowhead Business Overview
  124. 7.21.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  126. 7.21.5 Arrowhead Recent Developments
  127. 7.22 Alnylam
  128. 7.22.1 Alnylam Company Information
  129. 7.22.2 Alnylam Business Overview
  130. 7.22.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  132. 7.22.5 Alnylam Recent Developments
  133. 7.23 Akcea
  134. 7.23.1 Akcea Company Information
  135. 7.23.2 Akcea Business Overview
  136. 7.23.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  138. 7.23.5 Akcea Recent Developments
8 North America
  1. 8.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2021-2032)
  2. 8.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032)
  5. 8.3 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032)
  9. 8.5 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country
  11. 8.6.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2021-2032)
  2. 9.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country
  11. 9.6.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2021-2032)
  2. 10.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032)
  5. 10.3 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032)
  9. 10.5 China Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2021-2032)
  2. 11.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country
  11. 11.6.1 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2021-2032)
  2. 12.2 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country
  11. 12.6.1 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst